Stakeholders and the media have engaged in robust conversations about the Mifepristone rulings’ impacts that extend beyond abortion to other FDA decisions regarding historical court deference to agency interpretation of statutes and regulations, approvals of products that may face political opposition, and access and coverage variations across states.

Referent: Whitney A. Petrie

Veranstaltungsart: Webinar, CLE / CPD

Startdatum / -uhrzeit:
11 April 2024, 12:00 PM EDT
Enddatum / -uhrzeit:
11 April 2024, 1:00 PM EDT

In this CLE program, leading litigation and regulatory attorneys address the implications of the landmark mifepristone litigation for women’s health, life science companies, administrative law, and the future of healthcare in America.